 Lymphoma, Mantle-Cell
"Lymphoma, Mantle-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
| Descriptor ID |
D020522
|
| MeSH Number(s) |
C04.557.386.480.525 C15.604.515.569.480.525 C20.683.515.761.480.525
|
| Concept/Terms |
Lymphoma, Mantle-Cell- Lymphoma, Mantle-Cell
- Lymphoma, Mantle Cell
- Lymphomas, Mantle-Cell
- Mantle-Cell Lymphomas
- Mantle-Zone Lymphoma
- Lymphoma, Mantle-Zone
- Lymphomas, Mantle-Zone
- Mantle Zone Lymphoma
- Mantle-Zone Lymphomas
- Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
- Diffuse Lymphocytic Lymphoma, Poorly Differentiated
- Lymphoma, Small-Cell, Centrocytic
- Lymphocytic Lymphoma, Diffuse, Poorly-Differentiated
- Lymphoma, Centrocytic Small-Cell
- Centrocytic Small-Cell Lymphoma
- Centrocytic Small-Cell Lymphomas
- Lymphoma, Centrocytic Small Cell
- Lymphomas, Centrocytic Small-Cell
- Small-Cell Lymphoma, Centrocytic
- Small-Cell Lymphomas, Centrocytic
- Lymphoma, Lymphocytic, Diffuse, Intermediate Differentiated
- Lymphoma, Lymphocytic, Diffuse, Poorly-Differentiated
- Mantle-Cell Lymphoma
- Mantle Cell Lymphoma
- Lymphocytic Lymphoma, Diffuse, Poorly Differentiated
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Mantle-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Mantle-Cell".
This graph shows the total number of publications written about "Lymphoma, Mantle-Cell" by people in this website by year, and whether "Lymphoma, Mantle-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2009 | 2 | 0 | 2 | | 2010 | 1 | 1 | 2 | | 2011 | 1 | 1 | 2 | | 2012 | 1 | 0 | 1 | | 2013 | 3 | 0 | 3 | | 2015 | 1 | 0 | 1 | | 2017 | 1 | 1 | 2 | | 2018 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, Mantle-Cell" by people in Profiles.
-
Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, Sharma S, Lee J, Shacham S, Landesman Y, Maltsev N, Lu P, Wang YL. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of I?B. Mol Cancer Ther. 2018 12; 17(12):2564-2574.
-
Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, Venkataraman G, Huang S, Zhang H, Alikhan M, Lu P, Guo A, Galanina N, Andrade J, Wang ML, Wang YL. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018 08 28; 2(16):2039-2051.
-
Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res. 2017 Aug 01; 23(15):4212-4223.
-
Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017 Apr; 4(4):e176-e182.
-
Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun D, Jakubowiak A, Malek SN, Talpaz M, Donato NJ. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 2015 Jun 04; 125(23):3588-97.
-
Katz SG, Labelle JL, Meng H, Valeriano RP, Fisher JK, Sun H, Rodig SJ, Kleinstein SH, Walensky LD. Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells. Blood. 2014 Feb 06; 123(6):884-93.
-
Nabhan C, Ollberding NJ, Villines D, Chiu BC, Caces DB, Valdez TV, Ghielmini M, Hsu Schmitz SF, Smith SM. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas. Leuk Lymphoma. 2014 Jun; 55(6):1288-94.
-
Aschebrook-Kilfoy B, Caces DB, Ollberding NJ, Smith SM, Chiu BC. An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma. 2013 Aug; 54(8):1677-83.
-
Smith SM. Targeting mTOR in mantle cell lymphoma: current and future directions. Best Pract Res Clin Haematol. 2012 Jun; 25(2):175-83.
-
Liu H, Johnson JL, Koval G, Malnassy G, Sher D, Damon LE, Hsi ED, Bucci DM, Linker CA, Cheson BD, Stock W. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012 Apr; 97(4):579-85.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|